Under the terms of the agreement, Desitin will oversee, and be responsible for the expenses related to, all clinical development, regulatory approvals and commercialization efforts required to market and sell sumatriptan DosePro across Europe. Zogenix will be responsible for the manufacture and supply of commercial product, and will receive a transfer price payment on manufactured product and royalty payments based on sales of the product upon commercialization. Zogenix retains full commercial rights to sumatriptan DosePro in the US, Canada, Asia and certain other countries.
Roger Hawley, CEO of Zogenix, said: “This license agreement expands the potential reach for sumatriptan DosePro beyond the US, where, subject to regulatory approval, Zogenix is preparing to commercialize sumatriptan DosePro ourselves. We look forward to seeing sumatriptan DosePro advance through these steps and launch in the European marketplace.”